Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
02 nov. 2023 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to...
Ultragenyx anuncia que Mepsevii® (Vestronidasa alfa) ya está aprobado para su inclusión en el Compendio Nacional de Medicamentos de México para el tratamiento de la Mucopolisacaridosis VII (MPS VII)
01 nov. 2023 18h34 HE
|
Ultragenyx Pharmaceutical Inc.
CIUDAD DE MÉXICO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., una compañía biofarmacéutica dedicada al desarrollo y comercialización de terapias novedosas para...
Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update
26 oct. 2023 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
23 oct. 2023 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 oct. 2023 16h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
18 oct. 2023 21h16 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Proposed Public Offering of Common Stock
17 oct. 2023 16h02 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease
16 oct. 2023 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
Ultragenyx today will provide updates on its development pipeline and gene therapy portfolio at an Analyst Day in New York City and by webcast.
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
14 oct. 2023 16h30 HE
|
Ultragenyx Pharmaceutical Inc.; Mereo Biopharma
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12 oct. 2023 17h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...